Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2021-08-16 Earnings Release
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 16, 2021, reporting the financial results for the quarter ended June 30, 2021. It includes a press release as an exhibit announcing quarterly financial results. The text explicitly states it is a current report and the press release is furnished as an exhibit. The document length is 3459 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than the full earnings report itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). The document is not the full quarterly report (IR), nor is it a regulatory filing or report publication announcement. Therefore, the correct classification is Earnings Release (ER).
2021-08-16 English
FORM 4
Director's Dealing
2021-07-07 English
FORM 4
Director's Dealing
2021-07-07 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 8, 2021, by Praxis Precision Medicines, Inc. The key content is the submission of matters to a vote of security holders at the 2021 Annual Meeting of Stockholders. It details the voting results for the election of a Class I Director and the ratification of the appointment of the independent registered public accounting firm. The document explicitly reports the official results of shareholder votes at the Annual Meeting. There is no indication that this is a proxy statement, a full annual report, or other types of filings. The focus on voting results aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 4136 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the appropriate classification is DVA with high confidence.
2021-06-10 English
FORM 4
Director's Dealing
2021-06-09 English
FORM 4
Director's Dealing
2021-06-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.